Vijay Samant
Director/Board Member at Xiconic Pharmaceuticals LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Albert Marchio | M | 72 | 4 years | |
| Aaron Fox-Collis | M | - | 4 years | |
| Patricia Russo | F | 71 | 29 years | |
| Elaine Heron | M | 76 | 22 years | |
| Brian Mueller | M | 50 | 22 years | |
| Caroline Litchfield | F | 55 | 34 years | |
| George Bickerstaff | M | 68 |
International Vaccine Institute
 International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | 15 years |
| Donald Quest | M | 83 |
The Trustees of Columbia University in The City of New York
| 48 years |
| Brian Pusch | M | - |
Xiconic Pharmaceuticals LLC
| - |
| Nancy Seretta | F | - | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert P. Luciano | M | - | 23 years | |
| Georgia Erbez | F | 57 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 years |
| Andrew Sklawer | M | 41 | 14 years | |
| Kenneth Frazier | M | 69 | 30 years | |
| Richard Kogan | M | 81 | 21 years | |
| Timothy Walbert | M | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 6 years |
| Julie Smith | F | 53 | - | |
| Gary Lyons | M | 73 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 26 years |
| P. Vagelos | M | 94 | 19 years | |
| Suzanne Bruhn | M | 60 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 5 years |
| Deepak Chadha | M | 54 | 7 years | |
| George Morrow | M | 72 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 19 years |
| Paul Grint | M | 66 |
AmpliPhi Biosciences Corp.
 AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 4 years |
| Raymond Gilmartin | M | 82 | 2 years | |
| Jill Marie Church | F | 62 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
| Yazdi Piroj Dandiwala | M | 73 |
University of Mumbai
| 10 years |
| Anthony W. D'Souza | M | - |
University of Mumbai
| 5 years |
| Narendra Damodar Jadhav | M | 71 |
University of Mumbai
| 6 years |
| Stephen Sherwin | M | 75 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 2 years |
| Shashank N. Desai | M | - |
University of Mumbai
| 7 years |
| Larry G. Edwards | M | 52 | 15 years | |
| Alan R. Engbring | M | - |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 17 years |
| Joseph Romanelli | M | 50 | 19 years | |
| Reginald Hardy | M | 64 | 14 years | |
| Kenneth Bartizal | M | 72 | 20 years | |
| Igor Bilinsky | M | 51 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 years |
| Jill Broadfoot | F | 63 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 9 years |
| David Gionco | M | 63 | 3 years | |
| Bob H. Campbell | M | 86 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 10 years |
| Rajendra Kumar Aneja | M | 74 |
University of Mumbai
| 6 years |
| Keith D. Hall | M | 62 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 15 years |
| Gary Davis | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Frank Lanza | M | 62 | - | |
| Joshua S. Rubenstein | M | - |
The Trustees of Columbia University in The City of New York
| 7 years |
| Girish Nadkarni | M | - |
University of Mumbai
| 7 years |
| Alka Marezban Bharucha | F | 67 |
University of Mumbai
| 7 years |
| Robert Brown | M | 62 | 4 years | |
| Ramamurthy Viraraghavan | M | 70 |
University of Mumbai
| 6 years |
| Anders Klein | M | 71 |
The Trustees of Columbia University in The City of New York
| 6 years |
| Maria Matesanz | F | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Ben Golub | M | 66 |
MIT Sloan School of Management
| 3 years |
| Larry Smith | M | 63 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 16 years |
| David E. Bosher | M | 70 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 years |
| Bharat Kumar Khaitan | M | 69 |
University of Mumbai
| 6 years |
| David McAvoy | M | 62 | 4 years | |
| Anthony Alan Ramos | M | 57 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 14 years |
| Richard Henriques | M | 68 | 27 years | |
| Caroline Dorsa | F | 64 | 22 years | |
| William Harrison | M | 80 | - | |
| Anne Tatlock | F | 84 | - | |
| Laura Sepp-Lorenzino | M | 63 | 15 years | |
| John J Horan | M | - | 6 years | |
| Fred W. Hill | M | 73 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Raymond Anderson | M | 82 | 4 years | |
| Donald S. Brooks | M | 88 | - | |
| Thomas Shenk | M | 77 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 4 years |
| Paul K. Ross | M | - | - | |
| M. Scott Salka | M | 62 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | 2 years |
| Fredric D. Price | M | 78 | 4 years | |
| John R. Rehayem | M | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Louis C. Drapeau | M | 79 | 3 years | |
| Joshua Grass | M | - | 14 years | |
| Richard M. Beleson | M | 70 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 6 years |
| Marino Carol | F | - | 8 years | |
| Mammen P. Mammen | M | 60 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
| Carolyn Nannini Dolan | F | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Robert C. Merton | M | 79 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 17 years |
| David C. Kaslow | M | 65 |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | - |
| Wendy Yarno | F | 69 | 9 years | |
| Richard Markham | M | 73 | 20 years | |
| Dan Veru | M | 62 | 8 years | |
| Vasudev Krishna Murti | M | 72 |
University of Mumbai
| 4 years |
| Himanshu Patel | M | 71 |
University of Mumbai
| 4 years |
| Sunilkumar Dayama | M | 68 |
University of Mumbai
| 4 years |
| Mitaram Ramlal Jangid | M | 67 |
University of Mumbai
| 4 years |
| Rahul Merchant | M | 67 |
University of Mumbai
| 4 years |
| Mayank D. Sampat | M | 68 |
University of Mumbai
| 4 years |
| Dilipkumar Mulchand Lotia | M | - |
University of Mumbai
| 4 years |
| Santosh Kekre | M | 67 |
University of Mumbai
| 4 years |
| Amarjit Singh | M | 74 |
University of Mumbai
| 4 years |
| Himanshu Chaitanya Patel | M | 70 |
University of Mumbai
| 4 years |
| John W. Wallen | M | 66 | 6 years | |
| Anil D. Harish | M | 70 |
University of Mumbai
| 3 years |
| Madhu Rama Chandra Rao | M | 72 |
University of Mumbai
| 4 years |
| William D. Ju | M | 67 | 6 years | |
| Srikant T. Madhav Datar | M | 70 |
University of Mumbai
| 4 years |
| Anand R. Baichwal | M | 69 |
University of Mumbai
| 4 years |
| Sanjay Subhedar | M | - |
University of Mumbai
| 4 years |
| Mahendra Gupta | M | 68 |
University of Mumbai
| 4 years |
| Michael P. Doyle | M | - | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 74 | 74.00% |
| India | 25 | 25.00% |
| South Korea | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Vijay Samant
- Personal Network
